Proxima Raises $80 Million to Develop AI-Driven Drugs Modulating Protein-Protein Interactions

Proxima, a biotech startup, has raised $80 million in seed funding to accelerate the development of AI-driven drugs that modulate protein-to-protein interactions. The funding round was led by DCVC and NVentures, with participation from Roivant Sciences, Braidwell, and institutional investors. Proxima aims to create a data foundation to support rational drug design and has established partnerships with major pharmaceutical players. The company plans to enter clinical trials with multiple programs in 2026.